Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 0.72 |
| ▸ | HTR2C | P28335 | 6/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143258 | 0.87 | HTR2A (0.62) | HTR2AHTR2CKCNH2KMT2ATMEM97 | |
| SCHEMBL3148091 | 0.83 | HTR2A (0.56) | HTR2AHTR2CKCNH2TMEM97 | |
| SCHEMBL3143861 | 0.83 | HTR2A (0.56) | HTR2AHTR2CKCNH2TMEM97 | |
| SCHEMBL3143852 | 0.83 | HTR2A (0.56) | HTR2AHTR2CKCNH2TMEM97 | |
| SCHEMBL3144485 | 0.82 | HTR2A (0.62) | HTR2AHTR2CMEN1KMT2APRKAA2 | |
| SCHEMBL27787833 | 0.81 | HTR2A (0.67) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3139495 | 0.81 | HTR2A (1.00) | HTR2AHTR2CKCNH2 | |
| SCHEMBL4783828 | 0.80 | HTR2A (0.62) | HTR2AHTR2CKCNH2MEN1KMT2A | |
| SCHEMBL27787836 | 0.80 | HTR2A (0.66) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3134453 | 0.80 | HTR2A (0.71) | HTR2AHTR2CPRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434692-B2 | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | claimed |
| EP-2066641-B1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2014-06-04 | — | — | EP | claimed |
| US-20130217700-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | claimed |
| US-20100004264-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2010-01-07 | — | — | US | claimed |
| EP-2066641-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-06-10 | — | — | EP | claimed |
| WO-2008042388-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | claimed |
| US-11304932-B2 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | AXOVANT SCIENCES GMBH (CH) | 2022-04-19 | — | — | US | disclosed |
| US-20210380537-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210380537-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210177804-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS ASSOCIATED WITH A NEURODEGENERATIVE DISEASE | AXOVANT SCIENCES GMBH (CH) | 2021-06-17 | — | — | US | disclosed |
| US-20210177804-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS ASSOCIATED WITH A NEURODEGENERATIVE DISEASE | AXOVANT SCIENCES GMBH (CH) | 2021-06-17 | — | — | US | disclosed |
| US-20210128528-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | AXOVANT SCIENCES GMBH (CH) | 2021-05-06 | — | — | US | disclosed |
| US-20210128528-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | AXOVANT SCIENCES GMBH (CH) | 2021-05-06 | — | — | US | disclosed |
| CN-101611013-B | As 5-HT2APyrazole derivatives of serotonin receptor modulators for the treatment of disorders related thereto | ARENA PHARM INC | 2012-09-05 | — | — | CN | disclosed |
| US-20100004264-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20100004264-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20100004264-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2010-01-07 | — | — | US | disclosed |
| EP-2066641-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008042388-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008042388-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004264-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2B | HTR2A 2/4885HTR2C 7/4885KCNH2 527/4885 |
| US-20130217700-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 580/4885 |
| US-11304932-B2 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 4/4885KCNH2 1575/4885 |
| US-20210380537-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2B | HTR2A 2/4885HTR2C 7/4885KCNH2 527/4885 |
| US-20210177804-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS ASSOCIATED WITH A NEURODEGENERATIVE DISEASE | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 4/4885KCNH2 1575/4885 |
| US-20210128528-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | HTR2A, HTR1A, HTR3B | HTR2A 1/4885HTR2C 5/4885KCNH2 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.